No Data
X4 Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
BOSTON, May 13, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that management
X4 Pharma Gains on New $125 Financing
Express News | X4 Pharmaceuticals Announces $125M Capital Infusion From $105M Sale of Priority Review Voucher And $20M Drawdown From Existing Loan Facility, Extends Projected Cash Runway Into Late 2025
X4 Pharmaceuticals Advances With Strategic Financial Moves
Express News | X4: $125 Mln of Non-Dilutive Capital Extends Projected Cash Runway Into Late 2025, Excluding Expected Commercial Sales From Xolremdi
Express News | X4 Pharmaceuticals Announces $125 Million Capital Infusion From $105 Million Sale of Priority Review Voucher and $20 Million Drawdown From Existing Loan Facility
The Real Wojak : Do you have like a top 3-5 that you like more than all the other ones? This list is way too long